Disturbances in the endogenous cannabinoid (ECB) system in schizophrenia may contribute to their enhanced sensitivity to psychoactive substances, and the beneficial effects of second-generation antipsychotics for substance abuse in schizophrenia may involve modulatory effects on ECB. To verify these two assumptions, 29 patients (24 completers) with schizophrenia and substance use disorders (SUD) were treated with quetiapine for 12 weeks, and peripheral ECB levels were measured, using high-performance liquid chromatography/mass spectrometry, in patients (weeks 0, 6 and 12) and 17 healthy volunteers. Baseline anandamide levels were significantly higher in patients, relative to controls. This result is consistent with studies describing ECB dysfunctions in schizophrenia. SUD parameters improved during treatment, but no changes in ECB occurred over time. Improvements in substance abuse were probably not mediated by modulatory effects of quetiapine on ECB. Lastly, baseline anandamide predicted endpoint SUD scores (alcohol/ cannabis). Anandamide is a potential target for medications aimed at relieving SUD in schizophrenia.
Addington D. , Addington J. , Schissel B. (1990) A depression rating scale for schizophrenics . Schizophr Res3: 247-251
2.
Ameri A. (1999) The effects of cannabinoids on the brain . Progr Neurobiol58: 315-338
3.
Arnold J.C. (2005) The role of the endocannabinoid transmission in cocaine addiction . Pharmacol Biochem Behav81: 396-406
4.
Arseneault S. , Cannon M.R. , Murray R. , Caspi A. , Moffitt T.E. (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study . Brit Med J325: 1212-1213
5.
Basavarajappa B.S. , Hungund B.L. (2002) Neuromodulatory role of the endocannabinoid signalling system in alcoholism: an overview . Prostanglandins Leukot Essent Fatty Acids66: 287-299
6.
Brown E.S. , Nejtek V.A. , Perantie D.C. , Rajan Thomas N. , Rush A.J. (2003) Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation . J Clin Psychopharmacol23: 384-388
7.
Budney A.J. , Hughes J.R. , Moore B.A. , Vandrey R. (2004) Review of the validity and significance of cannabis withdrawal syndrome . Am J Psychiatry161: 1967-1977
8.
Chambers R.A. , Self D.W. (2002) Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia . Neuropsychopharmacology27: 889-905
9.
Colombo G. , Serra S. , Vacca G. , Carai M.A. , Gessa G.L. (2005) Endocannabinoid system and alcohol addiction: pharmacological studies . Pharmacol Biochem Behav81: 369-380
10.
Cravatt B.F. , Lichtman A.H. (2003) Fatty acid amid hydrolase: an emerging target in the endocannabinoid system . Curr Opin Chem Biol7: 469-475
11.
Dean B. , Sundram S. , Bradbury R. , Scarr E. , Copolov D. (2001) Studies on (3H)CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use . Neuroscience103: 9-15
12.
Del Arco I. , Navarro M. , Bilbao A. , Ferrer B. , Piomelli D. , Rodriguez de Fonseca F. (2002) Attenuation of spontaneous opiate withdrawal in mice by the anandamide transport inhibitor AM 404 . Eur J Pharmacol454: 103-104
13.
De Marchi N. , De Petrocellis L. , Orlando P. , Daniele F. , Fezza F. , Di Marzo V. (2003) Endocannabinoid signalling in the blood of patients with schizophrenia . Lipids Health Dis2: 5
14.
De Vries T.J. , Homberg J.R. , Binnekade R. , Raaso H. , Schoffelmeer A.N. (2003) Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats . Psychopharmacology168: 164-169
15.
De Vries T.J. , Shaham Y. , Homberg J.R. , Crombag H. , Schuurman K. , Dieben J. , Vanderschuren L.J. , Schoffelmeer A.N. (2001) A cannabinoid mechanism in relapse to cocaine seeking . Nat Med7: 1151-1154
16.
Drake R.E. , Osher F.C. , Noordsy D.L. , Hurlbut S.C. , Teague G.B. , Beaudett M.S. (1990) Diagnosis of alcohol use disorders in schizophrenia . Schizophr Bull16: 57-67
17.
D'Souza D.C. , Perry E. , MacDougall L. , Ammerman Y. , Cooper T. , Wu Y.T. , Braley G. , Guerguieva R. , Krystal J.H. (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis . Neuropsychopharmacology29: 1558-1572
18.
Emrich H.M. , Leweke M.F. , Schneider U. (1997) Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system . Pharm Bioch Behav56: 803-807
19.
Falck-Ytter Y. , McCullough, A.J. (2000) Nutritional effects of alcoholism . Curr Gastroenterol Rep2: 331-336
20.
Fu J. , Gaetani S. , Oveisi F. , Lo Verme J. , Serrano A. , Rodriguez de Fonseca F. , Rosengarth A. , Luecke H. , Di Giacomo B. , Tarzia G. , Piomelli D. (2003) Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha . Nature425: 90-93
21.
Garver D.L. , Tamas R.L. , Holcomb J.A. (2003) Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype . Neuropsychopharmacology28: 1515-1520
22.
Giuffrida A. , Leweke M.F. , Gerth C.W. , Schreiber D. , Koethe D. , Faulhaber J. , Klosterkotter J. , Piomelli D. (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms . Neuropsychopharmacology29: 2108-2114
23.
Giuffrida A. , Rodriguez de Fonseca F. , Piomelli D. (2000) Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry . Anal Biochem280: 87-93
24.
Giuffrida A. , Parsons L.H. , Kerr T.M. Rodriguezde Fonseca F. , Navarro M. , Piomelli D. (1999) Dopamine activation of endogenous cannabinoid signalling in dorsal striatum . Nat Neurosci2: 358-363
25.
Gonsiorek W. , Lunn C. , Fan X. , Narula S. , Lundell D. , Hipkin RW (2000). Endocannabinoid 2-arachidonylglycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide . Mol Pharmacol;57: 1045-1050.
26.
Green A.I. , Salomon M.S. , Brenner M.J. , Rawlins K. (2002) Treatment of schizophrenia and comorbid substance use disorder . Curr Drug Targets CNS Neurol Disord1: 129-139
27.
Huestis M.A. , Gorelick D.A. , Heishman S.J. , Preston K.L. , Nelson R.A. , Moolchan E.T. , Frank R.A. (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoids receptor antagonist (SR141716A) . Arch Gen Psychiatry58: 322-328
28.
Kay S.R. , Fiszbein A. , Opler L.A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia . Schizophr Bull13: 261-276
29.
Lallemand F. , Soubrie P. , De Witte P. (2001) Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration . Alcohol Clin Exp Res25: 1317-1323
30.
Leroy S. , Griffon N. , Bourdel M.C. , Olié J.P. , Poirier M.F. , Krebs M.O. (2001) Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1 . Am J Med Genetics105: 749-752
31.
Leweke F.M. , Giuffrida A. , Wursted U. , Emrich H.M. , Piomelli D. (1999) Elevated endogenous cannabinoids in schizophrenia . Neuroreport10: 1665-1669
32.
Linszen D.H. , Dingemans P.M. , Lenior M.E. (1994) Cannabis abuse and the course of recent-onset schizophrenic disorders . Arch Gen Psychiatry51: 273-279
33.
Lo Verme J. , Fu J. , Astarita G. , La Rana G. , Russo R. , Calignano A. , Piomelli D. (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide . Mol Pharmacol67: 15-19
34.
Meltzer H.Y. , Li Z. , Kaneda Y. , Ichikawa J. (2003) Serotonin receptors: their key role in drugs to treat schizophrenia . Progr Neuropsychopharmacol Biol Psychiatry27: 1159-1172
35.
Moghaddam B. , Krystal J.H. (2003) Chapter 19: the neurochemistry of schizophrenia . In Hirsch SR, Weinberger D (eds), Schizophrenia, 2nd edn. Blackwell Science, Massachusetts , pp. 349-364
36.
Müller D.J. , Muglia P. , Fortune T. , Kennedy J.L. (2004) Pharmacogenetics of antipsychotic-induced weight gain . Pharmacol Res49: 309-329
37.
Newcomer J.W. (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review . CNS Drugs19(Suppl 1): 1-93
38.
Nunez L.A. , Gurpegui M. (2002) Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia . Acta Psychiatr Scand105: 173-178
39.
Pope H.G. , Gruber A.J. , Yurgelun-Todd D. (1995) The residual neuropsychological effects of cannabis: the current status of research . Drug Alcohol Depend38: 25-34
40.
Pope H.G. , Gruber A.J. , Yurgelin-Todd D. (2001) Residual neuropsychologic effects of cannabis . Curr Psychiatry Rep3: 507-512
41.
Potvin S. , Stip E. , Roy J.Y. (2005) Chapter 7: Hedonic dysfunctions in schizophrenia: l'ennui à la folie. In Lang M V (ed.), Trends in schizophrenia research. Novascience Publishers, New York, pp. 119-149
42.
Potvin S. , Stip E. , Lipp O. , Mancini-Marië A. , Élie R. , Demers M.F. , Roy M.A. , Bouchard R.H. , Gendron A. (2006) Quetiapine in patients with schizophrenia-spectrum and substance use disorders: an open-label trial . Curr Med Res Opin22: 1277-1285
43.
Pryor S.R. (2000) Is platelet release of 2-arachidonoylglycerol a mediator of cognitive deficits? An endocannabinoid theory of schizophrenia and arousal . Med Hypotheses55: 494-501
44.
Regier D.A. , Farmer M.E. , Rae D.S. , Locke B.Z. , Keith S.J. , Judd L.L. , Goodwin F.K. (1990) Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study . JAMA264: 2511-2518
45.
Semple D.M. , McIntosh A.M. , Lawrie S.M. (2005) Cannabis as a risk factor for psychosis: systematic review . J Psychopharmacol19: 187-194
46.
Sobell L.C. , Sobell M.B. (1992) Timeline follow-back: a technique for assessing self-reported alcohol consumption. In Littren R Z , Allen J P (eds), Measuring alcohol consumptions: psychosocial and biochemical methods. Human Press, Towota, pp. 41-72
47.
Solowij N. , Grenyer B F S (2002) Chapter 27: Long-term effects of cannabis on psyche and cognition. In Grotenhermen F , Russo E (eds), Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Haworth Press, New York, pp. 299-311
48.
Sparling P.B. , Giuffrida A. , Piomelli D. , Rosskopf L. , Dietrich A. (2003) Exercise activates the endocannabinoid system . Neuroreport14: 2209-2211
49.
Stella N. , Piomelli D. (2001) Receptor-dependent formation of endogenous cannabinoids in cortical neurons . Eur J Pharmacol425: 189-196
50.
Sundram S. , Copolov D. , Dean B. ( 2005) Clozapine decreases [3H] CP 55940 binding to the cannabinoid receptor in the rat nucleus accumbens . Naunyn-Schmiedeberg's Arch Pharmacol371: 428-433
51.
Szabo G. (1999) Consequences of alcohol consumption on host defense . Alcohol Alcohol34: 830-841
52.
Tsapakis E.M. , Guillin O. , Murray R.M. (2003) Does dopamine sensitization underlie the association between schizophrenia and drug abuse?Curr Opin Psychiatry16: S45-S52
